Healthcare Innovations
Many physicians considering investing with MDVP want to learn more about our portfolio companies and their proprietary technologies that are being developed to advance the medical field. Below is a small sample of our portfolio companies and their innovative technologies.
Don't see a company in your medical specialty? Contact us online or call (949) 225-4784 for more information – we will provide specifics about all the companies we invest in to physicians who qualify to invest with us. From this small sample of companies, we hope you can see how our Physician Limited Partners are able to nurture the next generation of healthcare technologies through their investment.
Portfolio Company MM
This company has developed an energy-producing catheter technology that selectively shrinks plaque in the arteries without disturbing surrounding healthy tissue. A stand-alone device that does not require post-treatment stenting and minimizes catheter exchanges, the company's catheter system makes treatment more convenient while saving significant time and money. The system is compatible with available intravascular imaging, allowing a physician to see areas of diseased tissue before, during, and after treatment. This novel technology is especially well suited for diffuse disease and vulnerable plaque.
Portfolio Company SI
SI is developing patent pending anti-inflammatory peptides for a variety of skin treatments. These peptides have proven as effective as cortisone without the side effects. Their leading product has demonstrated effectiveness and safety in topical treatment of hyperpigmentation and wounds. Other applications for development also are being investigated, including treatment of psoriasis and eczema as well as anti-aging indications such as wrinkle smoothing and skin re-tightening after sun-induced inflammation. With both pharmaceutical and cosmeceutical development, the company's products have significant market flexibility.
Portfolio Company RM
This company is leveraging its novel stent designs and biomaterials to improve the treatment of vascular disease. Its premier product is a bioresorbable coronary stent that is designed to fulfill the temporary need for a stent and then dissolve, leaving only the healed vessel behind. In preclinical testing, the stent has performed comparably to commercial steel stents in critical parameters including strength, flexibility, recoil, and visibility. With proper development, product launch, and support this company's products promise to revolutionize the treatment of coronary artery disease.
Portfolio Company NS
With a market of over $1.8 billion worldwide and over 400,000 procedures performed in the U.S. alone last year, liposuction is a dominant procedure in the cosmetic surgery arena. But the popularity of cosmetic body contouring would rise to remarkable heights if patients could achieve results similar to liposuction without an invasive surgical procedure. NS has invested in developing non-invasive lipoplasty using focused ultrasound energy to liquefy fat cells without breaching the surface of the skin. Its technology stands out from the competition due to its portability, affordability, and ability to subtly sculpt targeted areas of fat.
Portfolio Company PC
Anti-aging medicine is a rapidly expanding market, with virtually every medical discipline exploring life-extending and life-improving technologies. PC specializes in commercializing pharmaceutical technologies, with an emphasis on anti-aging applications and disease management. The company markets its portfolio of preventive therapies directly to consumers through medical professionals. With products that use naturally-derived substances, the company is free to forward health claims similar to pharmaceuticals, but without FDA regulation, giving an additional degree of marketing flexibility.
Portfolio Company IS
A development stage company, IS is building an enterprise based on becoming a leader in evaluating, acquiring, integrating, and commercializing advanced stem cell technologies and related therapies. Its goal is to become a stand-out in the field and leading innovator in the commercialization of stem cell research achievements by seeking to control a combination of compatible technological advances that could result in the acceleration to market of stem cell therapies for a variety of diseases.
With this small sample of portfolio companies, we hope you can get a better idea of what our investment strategy is all about. The General Partners at MDVP are healthcare technology experts. Our goal is to identify and collaborate with physicians who are committed to building world-class healthcare businesses. If you are interested in learning more about our investment model, find out if you qualify to become an investor or call (949) 225-4784 for more information about getting started.
